New screening platform leads to discovery of next-generation prodrugs for type 1 diabetes



With nearly 2 million Americans battling type 1 diabetes, it is no surprise that clinical therapies for the disease are constantly evolving and improving. In type 1 diabetes mellitus, the body’s immune system attacks and destroys insulin-producing β-cells. As a result, people living with type 1 diabetes lose insulin secretion and encounter difficulty regulating glucose levels—especially after meals. Drugs developed to proliferate β-cells often are inefficient and have off-target effects that can dysregulate other cell types and pancreatic hormone production.



Source link

Leave a Reply!

So glad to see you sticking around!

Want to be the first one to receive the new stuff?

Enter your email address below and we'll send you the goodies straight to your inbox.

Thank You For Subscribing!

This means the world to me!

Spamming is not included! Pinky promise.